LILLY USA, LLC — Lobbying Disclosure | Poliscope

LILLY USA, LLC

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

149

Firms Hired

Active Period

2009–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	6	2
2025	—	8	2
2024	—	8	2
2023	—	10	3
2022	—	12	3
2021	—	10	3
2020	—	9	2
2019	—	10	3
2018	—	8	2
2017	—	8	2
2016	—	13	3
2015	—	9	3
2014	—	8	2
2013	—	8	2
2012	—	10	2
2011	—	4	1
2010	—	5	2
2009	—	3	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
BROWNSTEIN HYATT FARBER SCHRECK, LLP	—	29
FORBES-TATE	—	28
FROGUECLARK, LLC	—	37
FORGE FEDERAL AFFAIRS LLC	—	35
CROSSROADS STRATEGIES, LLC	—	8
REPUBLIC CONSULTING, LLC	—	6
BOSE PUBLIC AFFAIRS GROUP	—	6

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	124
SENATE	105
Health & Human Services, Dept of (HHS)	14
Executive Office of the President (EOP)	5
Office of the Vice President of the United States	5
White House Office	5
Natl Economic Council (NEC)	2
Office of Management & Budget (OMB)	2
Commerce, Dept of (DOC)	1
Veterans Affairs, Dept of (VA)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medicare/Medicaid	Medicare/Medicaid	84
Health Issues	Health Issues	82
Pharmacy	Pharmacy	58
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	45
Trade (domestic/foreign)	Trade (domestic/foreign)	34
Copyright/Patent/Trademark	Copyright/Patent/Trademark	26
Budget/Appropriations	Budget/Appropriations	16
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	10
Telecommunications	Telecommunications	9
Natural Resources	Natural Resources	2

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 4231119th Congress

Treat and Reduce Obesity Act of 2025

2026 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 4231

H.R. 5316119th Congress

Drug Shortage Compounding Patient Access Act of 2025

2026 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5316

H.R. 5316119th Congress

Drug Shortage Compounding Patient Access Act of 2025

2026 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5316

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6509

Show 21 more cited filings

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6509

S. 1973119th Congress

Treat and Reduce Obesity Act of 2025

2026 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S. 1973

S. 3794119th Congress

SAFE Drugs Act of 2026

2026 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S. 3794

S. 3794119th Congress

SAFE Drugs Act of 2026

2026 · third_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S. 3794

H.R. 4231119th Congress

Treat and Reduce Obesity Act of 2025

2026 · second_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 4231

H.R. 5316119th Congress

Drug Shortage Compounding Patient Access Act of 2025

2026 · second_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5316

H.R. 5316119th Congress

Drug Shortage Compounding Patient Access Act of 2025

2026 · second_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5316

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · second_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6509

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · second_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6509

S. 1973119th Congress

Treat and Reduce Obesity Act of 2025

2026 · second_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S. 1973

S. 3794119th Congress

SAFE Drugs Act of 2026

2026 · second_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S. 3794

S. 3794119th Congress

SAFE Drugs Act of 2026

2026 · second_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S. 3794

H.R. 4231119th Congress

Treat and Reduce Obesity Act of 2025

2026 · first_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 4231

H.R. 5316119th Congress

Drug Shortage Compounding Patient Access Act of 2025

2026 · first_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5316

H.R. 5316119th Congress

Drug Shortage Compounding Patient Access Act of 2025

2026 · first_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5316

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · first_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6509

H.R. 6509119th Congress

SAFE Drugs Act of 2025

2026 · first_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 6509

S. 1973119th Congress

Treat and Reduce Obesity Act of 2025

2026 · first_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S. 1973

S. 3794119th Congress

SAFE Drugs Act of 2026

2026 · first_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S. 3794

S. 3794119th Congress

SAFE Drugs Act of 2026

2026 · first_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: S. 3794

H.R. 4231119th Congress

Treat and Reduce Obesity Act of 2025

2025 · fourth_quarter · Firm: FORBES-TATE

Open original LDA filing ↗

Cited source text and reported amounts

Client expense: — · Firm income: $50,000

Matched citations: H.R. 4231

Source: Senate LDA